Five specialty pharmaceutical trends to watch Posted on October 13, 2016 by henrykotula • Posted in Uncategorized • Tagged Biosimilars, Cancer Drug Development, CHSâ€1701, Epoetin alfa, FDA, Filgrastim, Noninterchangeable Biosimilar, Orphan Drug Development, Pegfilgrastim, Pharmaceutical Industry, Pharmaceutical Specialty Trends, SB2 infliximab • Leave a comment http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/five-specialty-pharmaceutical-trends-watch?cfcache=true&GUID=A13E56ED-9529-4BD1-98E9-318F5373C18F&rememberme=1&ts=13102016 Share this: Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Click to share on LinkedIn (Opens in new window) LinkedIn Like Loading...
HENRY KOTULA 